ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1314

Autoantibodies and Clinical Outcomes in Pulmonary Arterial Hypertension Associated with Connective Tissue Diseases

Yuko Shirota1, Tomonori Ishii2, Tsuyoshi Shirai1, Hiroshi Fujii1 and Hideo Harigae1, 1Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, Sendai, Japan, 2Clinical Research, Innovation and Education Center, Tohoku University Hospital, Sendai, Japan

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: autoantibodies, Connective tissue diseases and pulmonary complications

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 22, 2018

Title: Miscellaneous Rheumatic and Inflammatory Diseases Poster II: Interstitial Lung Disease, Still's Disease, FMF, Polychondritis

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Pulmonary arterial hypertension (PAH) associated with SSc (SSc-PAH) has a substantially worse prognosis as compared to other connective tissue diseases (CTD)-PAH. Although SSc-PAH are generally treated with pulmonary vasodilators, they could be additionally considered with intensive immunosuppressive therapies (IIT), if overlapping inflammatory autoimmune diseases such as SS and SLE. However, it has not been known their outcome. We assessed the detailed autoantibodies and discriminative clinical symptoms and followed up their outcomes.

Methods: This retrospective study included 50 PAH patients associated with SSc (n=17), SLE (n=18), primary SS (n=8), and MCTD (n=7) referred to our hospital between 2000 and 2018. We performed right-heart catheterization and PAH defined as mean pulmonary arterial pressure (mPAP) ≥25 mmHg and the pulmonary arterial wedge pressure (PCWP) ≤15 mmHg at rest. We obtained their serum and determined autoantibodies against cytoplasmic and cell-nuclear antigens, including centromere, Scl-70, RNA-polymerase III, centriole, NuMA1, RNP, Sm, SSA/Ro, SSA/Ro52, SSB, PM-Scl, fibrillarin, Th/To, Ku, dsDNA, nucleosomes, histones, ribosomal P-proteins. We treated all patients with pulmonary vasodilators, and additionally treated with IIT, including cyclophosphamide (IVCY500mg/month x 10 times) and steroid (prednisolone 1mg/kg for 4 weeks and tapered to 5-10mg) for most of SLE, pSS, and MCTD, and some of SSc overlapping inflammatory autoimmune symptoms. Survival analysis was performed using the Kaplan-Meier method, and cumulative survival rates were compared by log-rank tests.

Results: In terms of SSc, we divided into three groups because those were different outcomes, which were (1) overlapping SS diagnosed by ACR criteria(n=7), (2) with centriole antibodies(n=3), or (3) without SS/ centriole antibody(n=7). We treated some severe PAH with SSc overlapping SS by IVCY with half dose steroid(0.5mg/kg) and PAH improved. All of centriole-SSc had discriminative digital ulcer. The one of them had quite severe ulcer and IVCY was remarkably effective for both ulcer and PAH, then treated in the same way for others. There was significantly worse cumulative survival rate in SSc than in SLE, pSS. In terms of SSc subgroup, there was a trend towards a better survival rate in centriole and overlapping SS than in other SSc (Figure). Th/To, which was one of the marker of lcSSc, existed in two patients although the one did not have scleroderma. Ribosomal P antibody existed in 4 patients, however, 3 of them did not have any neuro-psychiatric-SLE symptoms.

Conclusion: Although SSc-PAH has a substantially poor prognosis, we found that SSc overlapping SS and centriole type SSc-PAH might have better outcome than other SSc associated PAH and we could consider IIT for them. However, we should consider the risk of renal crisis, digestive symptoms and other life-threatening symptoms before utilizing IIT for SSc.


Disclosure: Y. Shirota, None; T. Ishii, None; T. Shirai, None; H. Fujii, None; H. Harigae, None.

To cite this abstract in AMA style:

Shirota Y, Ishii T, Shirai T, Fujii H, Harigae H. Autoantibodies and Clinical Outcomes in Pulmonary Arterial Hypertension Associated with Connective Tissue Diseases [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/autoantibodies-and-clinical-outcomes-in-pulmonary-arterial-hypertension-associated-with-connective-tissue-diseases/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/autoantibodies-and-clinical-outcomes-in-pulmonary-arterial-hypertension-associated-with-connective-tissue-diseases/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology